Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03653546 | First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases(BM) | completed | Phase 2 / Phase 3 | 492 | Alpha Biopharma (Jiangsu) Co., Ltd.INDUSTRY | 4 | Sep 10, 2025 | clinicaltrials |
| NCT04694846 | Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use | completed | N/A | 19 | Thomas Jefferson UniversityOTHER |
| 1 |
| Sep 9, 2025 |
| clinicaltrials |
| NCT01737502 | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 29 | Mayo ClinicOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT04853017 | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors(AMPLIFY-201) | completed | Phase 1 | 25 | Elicio TherapeuticsINDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT03844464 | Safety and Efficacy of Lorbrena | completed | — | 1,290 | PfizerINDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT04879849 | A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers | completed | Phase 1 | 34 | TakedaINDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT03715205 | Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) | completed | Phase 4 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 29, 2025 | clinicaltrials |
| NCT04772989 | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies(ARC-12) | completed | Phase 1 | 94 | Arcus Biosciences, Inc.INDUSTRY | 3 | Aug 28, 2025 | clinicaltrials |
| NCT03977467 | Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor | completed | Phase 2 | 46 | SCRI Development Innovations, LLCOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT02819024 | Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography | completed | N/A | 6 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT03708328 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 134 | Hoffmann-La RocheINDUSTRY | 6 | Aug 20, 2025 | clinicaltrials |
| NCT05259696 | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)(GLIMMER-01) | completed | Phase 1 / Phase 2 | 69 | Palleon Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT05517083 | Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer | completed | N/A | 41 | Pusan National University HospitalOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT04951154 | A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer | completed | — | 33 | Janssen Research & Development, LLCINDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT01951482 | Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer | completed | Phase 3 | 160 | Sun Yat-sen UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT02623712 | The Watch the Spot Trial(WTS) | completed | N/A | 34,686 | Kaiser PermanenteOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07121387 | A Retrospective Cohort Analysis of SMARCA4-Deficient Lung Cancer | completed | — | 221 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT02475213 | Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer | completed | Phase 1 | 146 | MacroGenicsINDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT04206072 | D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC | completed | Phase 2 / Phase 3 | 362 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07111104 | Survival Efficacy of Combined Radiotherapy and Immunotherapy in Patients With Metastatic Non-small Cell Lung Carcinoma(ARIS) | completed | — | 350 | Hopitaux Prives de Metz, Groupe UNEOSOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT02681549 | Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 41 | Yale UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT05585034 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors | completed | Phase 1 | 60 | Xencor, Inc.INDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07065422 | AI Models for Predicting Occult Pleural Dissemination in NSCLC | completed | — | 326 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT05253807 | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration(FIGHT-210) | completed | Phase 2 | 8 | Incyte CorporationINDUSTRY | 5 | Aug 5, 2025 | clinicaltrials |
| NCT06617390 | A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line Treatments(RECAP) | completed | — | 1,041 | Daiichi SankyoINDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT00243867 | Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer | completed | Phase 3 | 518 | American Regent, Inc.INDUSTRY | 1 | Aug 1, 2025 | clinicaltrials |
| NCT05212285 | Prognostic Value of Sarcopenia and Nutritional Status in Early-stage Non-small Cell Lung Cancer | completed | — | 469 | Fudan UniversityOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07099105 | Subcostal Single-port Versus Intercostal Multi-port Robotic Lobectomy for Non-small Cell Lung Cancer(SP vs MP robot) | completed | — | 339 | Korea University Guro HospitalOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT00199615 | Follow-up of Patients With Curative-intent Surgical Resection for NSCLC | completed | N/A | 73 | University Hospital, LimogesOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT04830826 | A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China(ADDRESS) | completed | — | 1,490 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05292859 | Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs | completed | — | 7 | Alaunos TherapeuticsINDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05303493 | Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma | completed | Phase 1 | 45 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT02392455 | VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC) | completed | — | 817 | Boehringer IngelheimINDUSTRY | 1 | Jul 28, 2025 | clinicaltrials |
| NCT04051827 | Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 26 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Jul 28, 2025 | clinicaltrials |
| NCT00284778 | Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer | completed | Phase 3 | 150 | University Hospital, LimogesOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT04026412 | A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery(CheckMate73L) | completed | Phase 3 | 925 | Bristol-Myers SquibbINDUSTRY | 27 | Jul 24, 2025 | clinicaltrials |
| NCT05546905 | A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS) | completed | — | 206 | Pierre Fabre MedicamentINDUSTRY | 5 | Jul 22, 2025 | clinicaltrials |
| NCT00199758 | Study of an Early Change of a Chemotherapeutic Doublet Versus Four Cycles of Chemotherapy in Advanced Non Small Cell Lung Cancer | completed | Phase 2 | 227 | University Hospital, LimogesOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT04120454 | Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 6 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT04580485 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | completed | Phase 1 | 54 | Incyte CorporationINDUSTRY | 6 | Jul 11, 2025 | clinicaltrials |
| NCT07053215 | Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC | completed | N/A | 60 | The First Hospital of Hebei Medical UniversityOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT02191891 | Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 32 | Boehringer IngelheimINDUSTRY | 4 | Jun 25, 2025 | clinicaltrials |
| NCT06054152 | CX3CR1+T Cell Predict Immunotherapy Efficacy | completed | — | 150 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07036016 | Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1 | completed | — | 67,818 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Jun 25, 2025 | clinicaltrials |
| NCT02299141 | Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 20 | Washington University School of MedicineOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT03885765 | Complication and Lung Function Impairment Prediction Using Perfusion and CT Air Trapping(CLIPPCAIR) | completed | — | 160 | University Hospital, MontpellierOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT00981058 | First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin(SQUIRE) | completed | Phase 3 | 1,093 | Eli Lilly and CompanyINDUSTRY | 26 | Jun 18, 2025 | clinicaltrials |
| NCT02705820 | Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy(SWIPE) | completed | Phase 2 | 48 | Bank of Cyprus Oncology CentreOTHER | 1 | Jun 17, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 10, 2025source: clinicaltrials